500mg Film-Coated Tablet
500mg Film-Coated Tablet
100 in stock
Each film-coated tablet contains:
Cefuroxime Axetil USP
Eq. to Cefuroxime …. 500 mg
A white to off white coloured oblong shaped, biconvex film coated tablet with a break line on one side and plain in other side.
MECHANISM OF ACTION
Cefuroxime inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell walls biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall assembly is arrested.
Absorption: Oral (cefuroxime axetil): Increased when given with or shortly after food or infant formula ( 37% to 52%)
Distribution: Widely distributed to body tissue and fluids; crosses blood-brain barrier; therapeutic concentrations achieved in CFS even when meninges are not inflamed.
Protein binding: 33% to 50%
Bioavailability, axetil: Oral :37% to 52%
Neonates: less than or equal to 3 days: 5.1-5 8hours; 6-14 days: 2-4.2hours; 3-4 weeks: I-1 5 hours
Adults: 1-2 hours (prolonged in renal impairment)
Time to peak serum concentration: I.M.: Within 15-60 minutes.
Elimination: Primarily excreted 66% to 100% as unchanged drug in urine by both glomerular filtration and tubular secretion.
For the treatment of infections due to sensitive Gram-positive and Gram-negative bacteria. It is more active against Haemophilus influenzae and Neisseria gonorrhea. It is also used for Iyme disease and as surgical prophylaxis.
DOSAGE AND ADMINISTRATION
Adults: 500 mg twice daily. UTI 125 mg twice daily
Uncomplicated Urinary Tract Infections 125 mg twice daily
Respiratory Tract 250 to 500 mg twice daily
Infections Lyme disease 500 mg twice daily for 20 days
Children: (More than 3 months)
Uncomplicated Urinary Tract Infections & 125 mg twice daily or 10 mg/kg
Respiratory Tract twice daily to a max of 250 mg daily
Otitis Media 250 mg twice daily or 15 mg/kg twice daily
to a max of 500 mg daily
Or as directed by the physician.
Hypersensitivity to cefuroxime, any component, or cephalosporins.
1% to 10%:
Hematologic: Eosinophilia (7%) decreased hemoglobin and Hematocrit (10%)
Hepatic: Increased transaminases (4%), increased alkaline phosphatase (2%)
Local: Thrombophlebitis (I .7%) Anaphylaxis, erythema multiforme, toxic epidermal necrolysis, Stevens- Johnson syndrome, interstitial nephritis, dizziness, fever, headache, rash, vomiting, diarrhea, stomach cramps, Gl bleeding, colitis, neutropenia, leukopenia, increased creatinine, increased BUN, vaginitis, seizures, angioedema, pseudomembranous colitis. Other reactions with cephalosporins include toxic nephropathy, cholestatis, agranulocytosis, colitis, pancytopenia, aplastic anemia, hemorrhage, prolonged P T, encephalopathy, asterixis, neuromuscular excitability, serum-sickness reactions, superinfection.
Increased effect: High-dose probenecid decreases clearance.
Increased toxicity: Aminoglycosides increase nephrotoxic potential.
Modify dosage in patients with severe renal impairment, prolonged use may result in superinfection; use with caution in patients with a history of penicillin allergy, especially lgE mediated reactions (eg, anaphylaxis, urticaria); may cause antibiotic-associated colitis or colitis secondary to C. difficile.
Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
Store at temperatures not exceeding 300C.
Keep all medicines out of reach of children.
|Alu/Alu Blister Pack x 10’s (Box of 10’s)||SRP 400.00|
“For suspected adverse drug reaction, report to the FDA: www.fda.gov.ph“